Imeglimin (hydrochloride)

Imeglimin is an anti-hyperglycemic compound. It inhibits high-glucose- or tert-butyl hydroperoxide-induced cell death in HMEC-1 endothelial cells when used at a concentration of 100 µM. Imeglimin (100 µM) reduces tert-butyl hydroperoxide-induced cytochrome c levels, as well as mitochondrial membrane permeability without affecting mitochondrial respiration, in HMEC-1 cells. It decreases plasma glucose levels and increases plasma insulin levels in a rat model of high-fat diet-induced obesity when administered at a dose of 150 mg/kg. Imeglimin (100 mg/kg) also reduces colonic balloon-induced pain-related muscle contractions in rats. In vivo, imeglimin (100 mg/kg) reduces colonic hyperpermeability in a rat model of LPS-induced irritable bowel syndrome (IBS), an effect that can be reversed by the AMP-activated protein kinase (AMPK) inhibitor compound C (dorsomorphin, Cay-11967, Cay-21207) or the peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW 9662 (Cay-70785). Formulations containing imeglimin have been used in the treatment of type 2 diabetes.Formal Name: (6R)-1,6-dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, hydrochloride. CAS Number: 775351-61-6. Molecular Formula: C6H13N5 . XHCl. Formula Weight: 155.2. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Soluble, Methanol: Soluble. SMILES: CN(C1=NC(N)=N[C@@H](C)N1)C.Cl. InChi Code: InChI=1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3,/h4H,1-3H3,(H3,7,8,9,10),1H/t4-,/m1./s1. InChi Key: UXHLCYMTNMEXKZ-PGMHMLKASA-N.